J.Jpn. Surg. Soc.. 79(9): 1131-1133, 1978
Report on the annual meeting
STUDY ON ADJUVANT CHEMOTHERAPY WITH FUTRAFUL FOR GASTRIC CNACER
|
Dept. of Oncologic Surgery Res. Inst. for Microbial Diseases Osaka University Tetsuo Taguchi |
This study involved 2064 patients following gastrectomy from May 1975 to July 1976 in 297 cooperative hospitals in Japan.
All patients had been divided into group I (intermittent intravenous injection of moderate dose of Mitomycin C (MMC) and group II (massive intravenous injection of MMC) and then each of the groups was allocated at random to subgroup A (without Futraful) and subgroup B (with futraful, that is, MMC plus oral administration of Futraful during 3 months).
The data indicate that all of the back ground factors were statistically similar in proportion between subgroup A and subgroup B within groups I and II. Side effects (subjective and objective symptoms) were very slight during the period of such long-term therapy. The cases received over 20 mg of MMC were classified according to dose regimen of Futraful and one-year survival rates were assessed. The results revealed that in patients of clinical stages III and IV, the survival rates of subgroups I-B and II-B were about 10 per cent higher than those of the comparable subgroups respectively and improved in proportion to dose of Futraful. This surgical adjuvant chemotherapy appears very hopeful for a suitable means of the treatment for gastric cancer.
To read the PDF file you will need Adobe Reader installed on your computer.